Chief Scientific Officer

Dr. Gibson joined Regulus in April 2011 with a proven track record of success in the pharmaceutical industry. Having over 17 years of drug development experience, including the direction of strategy for oncology discovery efforts at Pfizer, he brings significant pharmaceutical research and development experience to Regulus. He joined Regulus from the Oncology Research Unit at Pfizer, La Jolla, where he most recently held positions as chief scientific officer and oncology therapeutic area head. Dr. Gibson also held leadership roles on Pfizer’s Oncology Business Unit leadership team and global leadership team of Pfizer’s Pharmatherapeutics Organization. Prior to his years at Pfizer, Dr. Gibson held positions at OSI Pharmaceuticals including chief scientific officer, senior director of cancer discovery and vice president of research. Dr. Gibson’s industry experience has also included service as a director for cancer research in the Department of Cancer and Osteoporosis for Bayer. Dr. Gibson has held numerous academic appointments, including associate professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. During his career, Dr. Gibson has served on the Experimental Therapeutics Study Section of the National Cancer Institute and has been actively involved with the American Association of Cancer Research. He is also a past president of the British Pharmaceutical Students Association. Dr. Gibson earned his Ph.D. in 1982 from the University of Aston in Birmingham, England.